• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分析上尿路尿路上皮癌中通过上尿路肿瘤起源、膀胱癌复发和肌层浸润性膀胱癌进展的生物学特征和转变。

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.

机构信息

Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan.

出版信息

Int J Mol Sci. 2022 May 5;23(9):5154. doi: 10.3390/ijms23095154.

DOI:10.3390/ijms23095154
PMID:35563543
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9105227/
Abstract

To evaluate biological characteristics and transitions of upper tract urothelial carcinoma (UTUC) through metachronous bladder tumors after radical nephroureterectomy (RNU), we conducted immunohistochemical (IHC) staining of tumor specimens of UTUC tumor origin, non-muscle-invasive bladder cancer (NMIBC) and MIBC progressed after intravesical recurrence (IVR), and bladder primary MIBC. Fibroblast growth factor receptor 3 (FGFR3), p53, cytokeratin 5/6 (CK5/6), and CK20 were stained to examine expression rates. After expression assessment with heatmap clustering, the overexpression of four biomarkers from UTUC origin to metachronous MIBC progression was analyzed with clinicopathological variables. We found that high CK20 and low CK5/6 expression were both observed in UTUC tumor origin and subsequent NMIBC after RNU. By investigating molecular expression in the IVR specimen, we observed that low pT stage bladder recurrence occupied the majority of CK20 high CK5/6 low expression, but would change to CK20 low CK5/6 high expression as it progressed to MIBC. UTUC metachronous MIBC has different characteristics compared with bladder primary MIBC, which comprises favorable biological features such as high FGFR3 expression, and follows favorable prognosis compared to those without FGFR3 expression. The present study demonstrated that the biological characteristics of UTUC tumor origin shifts from luminal to basal-like features with progression to MIBC, but FGFR3 expression taken over from UTUC origin may comprise a favorable entity compared to primary MIBC.

摘要

为了评估根治性肾输尿管切除术(RNU)后顺行膀胱癌发生的上尿路上皮癌(UTUC)的生物学特征和转移,我们对 UTUC 肿瘤起源、非肌肉浸润性膀胱癌(NMIBC)和肌层浸润性膀胱癌(MIBC)进行了免疫组织化学(IHC)染色肿瘤标本经膀胱内复发(IVR)后复发和膀胱原发性 MIBC。检测了成纤维细胞生长因子受体 3(FGFR3)、p53、细胞角蛋白 5/6(CK5/6)和 CK20 的表达率。在用热图聚类进行表达评估后,分析了从 UTUC 起源到顺行 MIBC 进展的四个生物标志物的过度表达与临床病理变量的关系。我们发现 UTUC 肿瘤起源和 RNU 后随后发生的 NMIBC 中均观察到 CK20 高和 CK5/6 低表达。通过研究 IVR 标本中的分子表达,我们观察到低 pT 期膀胱复发主要占据 CK20 高 CK5/6 低表达,但随着进展为 MIBC,它会变为 CK20 低 CK5/6 高表达。与原发性膀胱 MIBC 相比,UTUC 顺行 MIBC 具有不同的特征,包括 FGFR3 表达较高的有利生物学特征,并且与 FGFR3 无表达相比,预后较好。本研究表明,UTUC 肿瘤起源的生物学特征从腔型向基底样特征转变,进展为 MIBC,但 FGFR3 表达可能取代 UTUC 起源,构成比原发性 MIBC 更有利的实体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/8796c5c276de/ijms-23-05154-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/35fc9c4baa39/ijms-23-05154-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/ed0cec15c48e/ijms-23-05154-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/1c9fa6053188/ijms-23-05154-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/8796c5c276de/ijms-23-05154-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/35fc9c4baa39/ijms-23-05154-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/ed0cec15c48e/ijms-23-05154-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/1c9fa6053188/ijms-23-05154-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af5c/9105227/8796c5c276de/ijms-23-05154-g004.jpg

相似文献

1
Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.分析上尿路尿路上皮癌中通过上尿路肿瘤起源、膀胱癌复发和肌层浸润性膀胱癌进展的生物学特征和转变。
Int J Mol Sci. 2022 May 5;23(9):5154. doi: 10.3390/ijms23095154.
2
The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.上尿路尿路上皮癌肌层浸润性复发的临床病理特征。
Cancer Sci. 2021 Mar;112(3):1084-1094. doi: 10.1111/cas.14782. Epub 2021 Jan 11.
3
Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.免疫组织化学染色分析细胞角蛋白(CK)5/6、CD44 和 CK20 作为非肌肉浸润性乳头状上尿路尿路上皮癌的预后生物标志物。
Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2.
4
Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.根治性肾输尿管切除术治疗上尿路上皮癌后膀胱内卡介苗治疗后续非肌层浸润性膀胱癌的结果。
BJU Int. 2018 May;121(5):764-773. doi: 10.1111/bju.14111. Epub 2018 Jan 21.
5
Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.上尿路尿路上皮癌对非肌肉浸润性膀胱癌患者对卡介苗反应的影响。
BJU Int. 2021 Nov;128(5):568-574. doi: 10.1111/bju.15344. Epub 2021 Feb 15.
6
The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy.既往膀胱癌对接受根治性肾输尿管切除术患者复发的影响
Clin Genitourin Cancer. 2022 Jun;20(3):e190-e198. doi: 10.1016/j.clgc.2021.12.006. Epub 2021 Dec 11.
7
Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.非肌层浸润性膀胱肿瘤史对上尿路尿路上皮癌患者的预后意义。
Urol Oncol. 2013 Nov;31(8):1615-20. doi: 10.1016/j.urolonc.2012.03.004. Epub 2012 Apr 21.
8
Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.肾盂输尿管癌根治术后发生的肌层浸润性膀胱癌。
Urol Oncol. 2013 Nov;31(8):1643-9. doi: 10.1016/j.urolonc.2012.04.014. Epub 2012 May 15.
9
Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review.上尿路和膀胱尿路上皮癌的同时性和异时性:它们是否具有克隆相关性?系统评价。
Urol Oncol. 2020 Jun;38(6):590-598. doi: 10.1016/j.urolonc.2020.01.008. Epub 2020 Feb 11.
10
Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma.后腹腔镜肾输尿管全长切除术治疗上尿路尿路上皮癌术后膀胱内复发的危险因素分析。
BMC Urol. 2021 Dec 2;21(1):167. doi: 10.1186/s12894-021-00932-2.

引用本文的文献

1
Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group).高危上尿路尿路上皮癌的新辅助和辅助联合治疗与辅助治疗对比:一项倾向匹配多中心分析(ROBUUST 2.0国际协作组)
World J Urol. 2025 Apr 18;43(1):234. doi: 10.1007/s00345-025-05605-5.
2
Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy.上尿路尿路上皮癌病史对接受膀胱内化疗的非肌层浸润性膀胱癌患者的影响。
Sci Rep. 2025 Feb 18;15(1):5977. doi: 10.1038/s41598-025-89525-9.
3

本文引用的文献

1
Pparg signaling controls bladder cancer subtype and immune exclusion.PPARγ 信号通路调控膀胱癌亚型和免疫排斥。
Nat Commun. 2021 Oct 25;12(1):6160. doi: 10.1038/s41467-021-26421-6.
2
Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.同一患者的异时性和同时性上尿路和膀胱尿路上皮癌的表达分析。
J Urol. 2021 Sep;206(3):548-557. doi: 10.1097/JU.0000000000001788. Epub 2021 Apr 21.
3
Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma.
Management of Upper Tract Urothelial Carcinoma in a Double Collecting System Kidney.
双集合系统肾脏中上尿路尿路上皮癌的管理
J Pers Med. 2024 Jan 30;14(2):158. doi: 10.3390/jpm14020158.
4
Intravesical Recurrence after Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma Is Associated with Flexible Diagnostic Ureteroscopy, but Not with Rigid Diagnostic Ureteroscopy.上尿路尿路上皮癌患者根治性肾输尿管切除术后膀胱内复发与软性诊断性输尿管镜检查相关,但与硬性诊断性输尿管镜检查无关。
Cancers (Basel). 2022 Nov 16;14(22):5629. doi: 10.3390/cancers14225629.
成纤维细胞生长因子受体 3 与突变型 p53 的共表达及其与口咽鳞状细胞癌不良预后的关系。
PLoS One. 2021 Feb 24;16(2):e0247498. doi: 10.1371/journal.pone.0247498. eCollection 2021.
4
CK20 and CK5/6 Immunohistochemical Staining of Urothelial Neoplasms: A Perspective.尿路上皮肿瘤的CK20和CK5/6免疫组化染色:一种观点
Adv Urol. 2020 Nov 4;2020:4920236. doi: 10.1155/2020/4920236. eCollection 2020.
5
The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.上尿路尿路上皮癌肌层浸润性复发的临床病理特征。
Cancer Sci. 2021 Mar;112(3):1084-1094. doi: 10.1111/cas.14782. Epub 2021 Jan 11.
6
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?.在接受根治性膀胱切除术治疗的大型膀胱癌队列中检测 FGFR3 突变状态和 FGFR3 表达:对 FGFR3 靶向治疗的影响?
Eur Urol. 2020 Nov;78(5):682-687. doi: 10.1016/j.eururo.2020.07.002. Epub 2020 Jul 15.
7
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2020 年更新版。
Eur Urol. 2021 Jan;79(1):62-79. doi: 10.1016/j.eururo.2020.05.042. Epub 2020 Jun 24.
8
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.厄达替尼治疗局部晚期或转移性尿路上皮癌。
N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
9
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.上尿路尿路上皮癌具有管腔-乳头 T 细胞耗竭的结构和激活的 FGFR3 信号通路。
Nat Commun. 2019 Jul 5;10(1):2977. doi: 10.1038/s41467-019-10873-y.
10
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.预测非肌肉浸润性(Ta/T1)膀胱癌的结局:基于腔面/基底表型的分子分级的作用。
Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25.